NCT05979155View on ClinicalTrials.gov

A Study of NWY001 in Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

May 31, 2028

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

NWY001

Part 1: Participants will be given a single-dose of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.

BIOLOGICAL

NWY001

Part 2: Participants will be given RP2D of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Cancer, Guangzhou

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY